What does this research mean for the field?

The cost-effectiveness of antihyperlipemic therapy for primary prevention of coronary heart disease varies substantially, being highly cost-effective for younger patients with additional risk factors but potentially not cost-effective for older patients or those without additional risk factors. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research assesses the cost-effectiveness of antihyperlipemic therapy for preventing coronary heart disease in men with high cholesterol.

November 6, 1987JAMA

Cost-effectiveness of Antihyperlipemic Therapy in the Prevention of Coronary Heart Disease

View Full Paper

Ask AI

Bookmark

Authors

GOGerry OsterPolicy Analysis (United States)

Discussion

Member takes

Implication

Randomized trial evaluates cost-effectiveness of antihyperlipemic therapy in men aged 35-74, suggesting targeted treatment may benefit specific groups.

Key Points

This research assesses the cost-effectiveness of antihyperlipemic therapy for preventing coronary heart disease in men with high cholesterol.
Utilization of cholestyramine as a model for antihyperlipemic therapy
Analysis of cost-effectiveness across different age groups and risk factors
Exploration of treatment duration effects on cost-effectiveness
Cost-effectiveness ranges from $36,000 to over $1 million per year of life saved depending on demographic and risk factor variables.
Highest cost-effectiveness found in younger patients with additional coronary risk factors and shorter treatment duration.
Lower cost-effectiveness observed in older patients or those without additional coronary risk factors, particularly with lifelong treatment.

Cite This Study

Gerry Oster (1987) studied this question.

synapsesocial.com/papers/6a0770bc85d51e7cc75851e6 https://doi.org/10.1001/jama.1987.03400170067025

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates cost-effectiveness of antihyperlipemic therapy in men aged 35-74, suggesting targeted treatment may benefit specific groups.

Cost-effectiveness of Antihyperlipemic Therapy in the Prevention of Coronary Heart Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Cost-effectiveness of Antihyperlipemic Therapy in the Prevention of Coronary Heart Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider